BSE:532482

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. More Details


Snowflake Analysis

Flawless balance sheet with outstanding track record.

Share Price & News

How has Granules India's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 532482 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 532482's weekly volatility (6%) has been stable over the past year.


Market Performance


7 Day Return

10.4%

532482

3.7%

IN Pharmaceuticals

1.8%

IN Market


1 Year Return

222.6%

532482

47.6%

IN Pharmaceuticals

7.9%

IN Market

Return vs Industry: 532482 exceeded the Indian Pharmaceuticals industry which returned 47.6% over the past year.

Return vs Market: 532482 exceeded the Indian Market which returned 7.9% over the past year.


Shareholder returns

532482IndustryMarket
7 Day10.4%3.7%1.8%
30 Day7.4%4.5%10.8%
90 Day31.6%6.9%13.1%
1 Year223.9%222.6%49.3%47.6%10.0%7.9%
3 Year239.4%231.6%40.6%37.2%8.1%2.8%
5 Year178.7%168.5%9.4%5.6%55.3%43.6%

Long-Term Price Volatility Vs. Market

How volatile is Granules India's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Granules India undervalued compared to its fair value and its price relative to the market?

24.14x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 532482 (₹412.45) is trading above our estimate of fair value (₹144.36)

Significantly Below Fair Value: 532482 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 532482 is poor value based on its PE Ratio (24.1x) compared to the IN Pharmaceuticals industry average (21.2x).

PE vs Market: 532482 is poor value based on its PE Ratio (24.1x) compared to the Indian market (17.3x).


Price to Earnings Growth Ratio

PEG Ratio: 532482 is poor value based on its PEG Ratio (1.4x)


Price to Book Ratio

PB vs Industry: 532482 is overvalued based on its PB Ratio (5.4x) compared to the IN Pharmaceuticals industry average (2.2x).


Next Steps

Future Growth

How is Granules India forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

17.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 532482's forecast earnings growth (17.7% per year) is above the savings rate (7.2%).

Earnings vs Market: 532482's earnings (17.7% per year) are forecast to grow slower than the Indian market (24.5% per year).

High Growth Earnings: 532482's earnings are forecast to grow, but not significantly.

Revenue vs Market: 532482's revenue (15.2% per year) is forecast to grow faster than the Indian market (11.5% per year).

High Growth Revenue: 532482's revenue (15.2% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 532482's Return on Equity is forecast to be high in 3 years time (22.9%)


Next Steps

Past Performance

How has Granules India performed over the past 5 years?

26.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 532482 has high quality earnings.

Growing Profit Margin: 532482's current net profit margins (14.9%) are higher than last year (11.9%).


Past Earnings Growth Analysis

Earnings Trend: 532482's earnings have grown significantly by 26.8% per year over the past 5 years.

Accelerating Growth: 532482's earnings growth over the past year (42.2%) exceeds its 5-year average (26.8% per year).

Earnings vs Industry: 532482 earnings growth over the past year (42.2%) exceeded the Pharmaceuticals industry 24.6%.


Return on Equity

High ROE: 532482's Return on Equity (22.6%) is considered high.


Next Steps

Financial Health

How is Granules India's financial position?


Financial Position Analysis

Short Term Liabilities: 532482's short term assets (₹18.7B) exceed its short term liabilities (₹11.5B).

Long Term Liabilities: 532482's short term assets (₹18.7B) exceed its long term liabilities (₹4.3B).


Debt to Equity History and Analysis

Debt Level: 532482's debt to equity ratio (40%) is considered satisfactory.

Reducing Debt: 532482's debt to equity ratio has reduced from 73.1% to 40% over the past 5 years.

Debt Coverage: 532482's debt is well covered by operating cash flow (58.4%).

Interest Coverage: 532482's interest payments on its debt are well covered by EBIT (42.8x coverage).


Balance Sheet


Next Steps

Dividend

What is Granules India current dividend yield, its reliability and sustainability?

0.24%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 532482's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the Indian market (0.52%).

High Dividend: 532482's dividend (0.24%) is low compared to the top 25% of dividend payers in the Indian market (2.1%).


Stability and Growth of Payments

Stable Dividend: 532482 is not paying a notable dividend for the Indian market, therefore no need to check if payments are stable.

Growing Dividend: 532482 is not paying a notable dividend for the Indian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 532482 is not paying a notable dividend for the Indian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 532482's dividend in 3 years as they are not forecast to pay a notable one for the Indian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.3yrs

Average management tenure


CEO

Krishna Chigurupati (66 yo)

11.17yrs

Tenure

₹149,904,000

Compensation

Mr. Krishna Prasad Chigurupati, B.Sc. has been Managing Director of Granules India Limited since September 1, 2009. He serves as Chairman of Granules India Limited and has been its Non-Independent Executiv...


CEO Compensation Analysis

Compensation vs Market: Krishna's total compensation ($USD0.00) is below average for companies of similar size in the Indian market ($USD606.60K).

Compensation vs Earnings: Krishna's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Sandip Neogi
Chief Financial Officer1yr₹4.34mno data
Sivaram Guntamukkala
Chief Operating Officer1.83yrsno data0.020%
₹ 20.6m
Chaitanya Tummala
Company Secretary & Compliance Officer6.33yrs₹3.55mno data
Atul Dhavle
Chief Human Resources Officer & Head of Operational Excellenceno datano datano data
Harsha Chigurupati
Executive Director10.33yrs₹25.30mno data
M. Kumar
Senior Vice President of API Manufacturingno datano datano data
Krishna Chigurupati
Chairman & MD11.17yrs₹149.90m35.61%
₹ 36.4b
Sumanta Bajpayee
Head of Corporate Financeno datano datano data
P. S. Murthy
Senior Vice President of Human Resourcesno datano datano data
Desireddy Reddy
Senior Vice President of GPIno datano datano data
Pranesh Mathur
President of API Division10.33yrs₹3.56mno data
Kapur Nivaran
President of GUSAno datano datano data

6.3yrs

Average Tenure

53yo

Average Age

Experienced Management: 532482's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Harsha Chigurupati
Executive Director10.33yrs₹25.30mno data
Krishna Chigurupati
Chairman & MD11.17yrs₹149.90m35.61%
₹ 36.4b
Arun Sawhney
Non-Executive Independent Director2.08yrs₹780.00kno data
Arun Akinepally
Independent Non-Executive Director10.58yrs₹890.00k0.12%
₹ 117.6m
Uma Chigurupati
Non-Independent Executive Director8.5yrs₹164.45m3.82%
₹ 3.9b
Kolli Basava Rao
Non-Executive Non-Independent Director7.67yrs₹900.00k1.44%
₹ 1.5b
Priyanka Chigurupati
Executive Director of Granules Pharmaceuticals Inc.no data₹9.65m0.76%
₹ 771.5m
Jyothi Prasad
Lead Independent Directorno data₹570.00kno data
Robert Cunard
Non-Executive Independent Director1.83yrs₹440.00kno data

8.1yrs

Average Tenure

61yo

Average Age

Experienced Board: 532482's board of directors are considered experienced (8.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: 532482 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Granules India Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Granules India Limited
  • Ticker: 532482
  • Exchange: BSE
  • Founded: 1984
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: ₹102.139b
  • Shares outstanding: 247.64m
  • Website: https://www.granulesindia.com

Number of Employees


Location

  • Granules India Limited
  • My Home Hub
  • 2nd Floor
  • Hyderabad
  • 500081
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
532482BSE (Mumbai Stock Exchange)YesEquity SharesININRFeb 2003
GRANULESNSEI (National Stock Exchange of India)YesEquity SharesININRFeb 2003

Biography

Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. The company's APIs...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 12:18
End of Day Share Price2020/11/27 00:00
Earnings2020/09/30
Annual Earnings2020/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.